Watch ECOC. Know when insiders buy.
One email the day a filing lands. Free.
ECOC
ABVC BIOPHARMA, INC.
0.05
+0.00 +0.00%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$7.1MNET DEBT $92K52W 0.02 – 0.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$780K | −$737K | — | -0.03 | −$244K | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$1.6M | −$1.6M | — | -0.06 | −$894K | — | — | May 18 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.2M | −$2.8M | — | -0.11 | −$588K | — | — | Mar 3 |
| Q3 2025 · Sep 30 | $796K | +104.5% | 100.0% | −$2M | −$2M | — | -0.09 | −$965K | — | — | Mar 3 |
| Q2 2025 · Jun 30 | — | — | — | −$2.3M | −$2.3M | — | -0.13 | −$894K | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$693K | −$842K | — | -0.06 | −$540K | — | — | May 18 |
| Q4 2024 · Dec 31derived | $2K | −9.2% | 100.0% | −$705K | −$732K | — | -0.05 | −$702K | — | — | Mar 3 |
| Q3 2024 · Sep 30 | $389K | +2350.7% | 99.9% | −$302K | −$395K | — | -0.03 | $60K | — | — | Mar 3 |
| Q2 2024 · Jun 30 | $117K | — | 99.8% | −$860K | −$942K | — | -0.08 | −$211K | — | — | Aug 13 |
| Q1 2024 · Mar 31 | $1K | — | 77.0% | −$2.8M | −$2.8M | — | -0.29 | −$956K | — | — | Apr 30 |
| Q4 2023 · Dec 31derived | $2K | — | -6329.8% | −$512K | −$383K | — | 0.28 | −$430K | $0 | −$430K | Apr 15 |
| Q3 2023 · Sep 30 | $16K | — | -86.4% | −$2.2M | −$3.3M | — | -0.82 | −$1.4M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7.2M | −$7.9M | — | -0.39 | −$3M | — | — | — | — |
| FY2024 · to Dec 31 | $510K | 99.9% | −$4.7M | −$4.9M | -962.1% | -0.42 | −$1.8M | — | — | — | — |
| FY2023 · to Dec 31 | $152K | -98.1% | −$6.8M | −$7.8M | -5109.3% | -1.80 | −$4.2M | $21K | −$4.2M | — | — |
| FY2022 · to Dec 31 | $970K | 70.5% | −$15.1M | −$16.4M | -1693.5% | -5.19 | −$7.4M | $120K | −$7.5M | — | — |
| FY2021 · to Dec 31 | $356K | 98.6% | −$11.7M | −$12.8M | -3608.5% | -0.51 | −$7.6M | $18K | −$7.6M | — | — |
| FY2020 · to Dec 31 | $483K | 96.1% | −$8.5M | −$10.6M | -2193.1% | -0.50 | −$4.6M | — | — | — | — |
Every number comes from ABVC BIOPHARMA, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.